In malignancies such as kidney cancer and pancreatic neuroendocrine tumors where a therapeutic role of Sunitinib has been established [23–25], the absence of the VHL gene causes accumulation of HIFs and the production of several growth factors, including VEGF and PDGF against which Sunitinib has efficacy [23]. This evidence concerns the gene VHL and pancreatic neuroendocrine tumor.